DUBLIN--(BUSINESS WIRE)--The "Malignant Pleural Effusion - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Malignant Pleural Effusion - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively.
Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Malignant Pleural Effusion - Overview
Malignant Pleural Effusion - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Malignant Pleural Effusion - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Malignant Pleural Effusion - Companies Involved in Therapeutics Development
- Amgen Inc
- Biogen Inc
- BioSyngen Pte Ltd
- Clover Biopharmaceuticals
- Genelux Corp
- Gongwin Biopharm Holdings Co Ltd
- Hubei Soundny Bio-Tech Co Ltd
- Lipac Oncology LLC
Malignant Pleural Effusion - Drug Profiles
BG-00001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
BSG-001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
methotrexate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
olvimulogene nanivacirepvec - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
paclitaxel - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PTS-500 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
SCB-313 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
talimogene laherparepvec - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Malignant Pleural Effusion - Dormant Projects
Malignant Pleural Effusion - Product Development Milestones
- Featured News & Press Releases
- Jan 10, 2020: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Pleural Effusions (MPE)
- Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
- Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
- May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
- Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
- May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
- Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/q68rvb
